Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Pharmacokinetics, and Safety of CDP870 Without Coadministration of MTX in Japanese Active RA Patients in Whom MTX Cannot be Administrated.
Brief Summary: The objectives of this study are to verify the superiority in efficacy (American College of Rheumatology 20%: ACR20) and investigate the pharmacokinetics and safety of CDP870 versus placebo without coadministration of MTX in active RA patients in whom MTX cannot be administrated.


Options:
A: Arm Label: CDP870 200mg; Type: EXPERIMENTAL; Interventions: Drug: CDP870 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo of CDP870 | Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): CDP870 200mg | Intervention Type: DRUG; Name: Placebo of CDP870; Assigned to Arm(s): Placebo
B: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)
C: Arm Label: DB Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Double-blind Placebo | Arm Label: DB adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab | Arm Label: DB Adalimumab/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab | Arm Label: DB Placebo/OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab | Arm Label: DB Adalimumab/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Biological: Double-blind adalimumab, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Arm Label: DB Placebo/RE OL Adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Double-blind Placebo, Biological: Open-label Adalimumab, Biological: Open-labelAdalimumabRescue | Intervention Type: BIOLOGICAL; Name: Double-blind adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB adalimumab | Intervention Type: DRUG; Name: Double-blind Placebo; Assigned to Arm(s): DB Placebo, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-label Adalimumab; Assigned to Arm(s): DB Adalimumab/OL Adalimumab, DB Adalimumab/RE OL Adalimumab, DB Placebo/OL Adalimumab, DB Placebo/RE OL Adalimumab | Intervention Type: BIOLOGICAL; Name: Open-labelAdalimumabRescue; Assigned to Arm(s): DB Adalimumab/RE OL Adalimumab, DB Placebo/RE OL Adalimumab
D: Arm Label: Certolizumab pegol (CZP); Type: EXPERIMENTAL; Interventions: Drug: Certolizumab pegol (CZP) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Certolizumab pegol (CZP); Assigned to Arm(s): Certolizumab pegol (CZP) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A